DEB-TACE for Hepatocellular Carcinoma (QED)
Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes by Comparing Two Different Catheter Systems for DEB-TACE (QED Study)
Sponsor: Surefire Medical, Inc.
Terminated
Low enrollment
Other terminated trials from Surefire Medical, Inc.
- Hepatocellular Carcinoma · Phase NA · Dec 2018
- Hepatocellular Carcinoma of the Liver · Phase NA · Sep 2018
- Hepatocellular Carcinoma · Jun 2018
More terminations from Surefire Medical, Inc.
Other Hepatocellular Carcinoma trials with similar outcome
Listed as NCT02748161, this NA trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Surefire Medical, Inc., it has been updated 13 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Oct 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Oct 2021 [monthly]
Terminated NA
▶ Show 8 earlier versions
-
Jul 2018 — Jan 2021 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Recruiting NA
-
Nov 2017 — May 2018 [monthly]
Recruiting NA
-
Aug 2017 — Nov 2017 [monthly]
Recruiting NA
Status: Enrolling By Invitation → Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Enrolling By Invitation NA
-
Apr 2017 — Jun 2017 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Apr 2017 [monthly]
Enrolling By Invitation NA
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Surefire Medical, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .